

Alexander B Olawaiye

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3752381/publications.pdf>

Version: 2024-02-01

43
papers

2,485
citations

430874

18
h-index

302126

39
g-index

44
all docs

44
docs citations

44
times ranked

3182
citing authors

#	ARTICLE	IF	CITATIONS
1	Revised FIGO staging for carcinoma of the cervix uteri. International Journal of Gynecology and Obstetrics, 2019, 145, 129-135.	2.3	612
2	Endometrial cancer: A review and current management strategies: Part I. Gynecologic Oncology, 2014, 134, 385-392.	1.4	339
3	Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology, 2016, 34, 3460-3473.	1.6	318
4	Endometrial cancer: A review and current management strategies: Part II. Gynecologic Oncology, 2014, 134, 393-402.	1.4	305
5	Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial. Lancet Oncology, The, 2020, 21, 957-968.	10.7	140
6	Uterine sarcomas. International Journal of Gynecology and Obstetrics, 2018, 143, 51-58.	2.3	109
7	Impact of adjuvant chemotherapy with radiation for node-positive vulvar cancer: A National Cancer Data Base (NCDB) analysis. Gynecologic Oncology, 2015, 137, 365-372.	1.4	81
8	The new (Version 9) American Joint Committee on Cancer tumor, node, metastasis staging for cervical cancer. Ca-A Cancer Journal for Clinicians, 2021, 71, 287-298.	329.8	65
9	Cancer of the vulva: 2021 update. International Journal of Gynecology and Obstetrics, 2021, 155, 7-18.	2.3	58
10	Abdominal radical trachelectomy: Success and pitfalls in a general gynecologic oncology practice. Gynecologic Oncology, 2009, 112, 506-510.	1.4	54
11	Utility of pre-operative serum CA-125 in the management of uterine papillary serous carcinoma. Gynecologic Oncology, 2008, 110, 293-298.	1.4	53
12	FIGO staging for carcinoma of the vulva: 2021 revision. International Journal of Gynecology and Obstetrics, 2021, 155, 43-47.	2.3	42
13	Treatment of squamous cell vulvar cancer with the anti-EGFR tyrosine kinase inhibitor Tarceva. Gynecologic Oncology, 2007, 106, 628-630.	1.4	27
14	Factors associated with deciding between risk-reducing salpingo-oophorectomy and ovarian cancer screening among high-risk women enrolled in GOG-0199: An NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology, 2017, 145, 122-129.	1.4	21
15	Systemic Treatment of Metastatic/Recurrent Uterine Leiomyosarcoma: A Changing Paradigm. Oncologist, 2018, 23, 1533-1545.	3.7	21
16	Outcomes analysis of an alternative formulation of PEGylated liposomal doxorubicin in recurrent epithelial ovarian carcinoma during the drug shortage era. OncoTargets and Therapy, 2014, 7, 1409.	2.0	20
17	Neoadjuvant radiotherapy with or without chemotherapy followed by extrafascial hysterectomy for locally advanced endometrial cancer clinically extending to the cervix or parametria. Gynecologic Oncology, 2014, 135, 190-195.	1.4	20
18	Image-based multichannel vaginal cylinder brachytherapy for vaginal cancer. Brachytherapy, 2015, 14, 9-15.	0.5	20

#	ARTICLE	IF	CITATIONS
19	Does adjuvant chemotherapy dose modification have an impact on the outcome of patients diagnosed with advanced stage ovarian cancer? An NRG Oncology/Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2018, 151, 18-23.	1.4	18
20	Lymphnode staging update in the American Joint Committee on Cancer 8th Edition cancer staging manual. <i>Gynecologic Oncology</i> , 2018, 150, 7-8.	1.4	17
21	Pre-operative assessment and post-operative outcomes of elderly women with gynecologic cancers, primary analysis of NRG CC-002: An NRG oncology group/gynecologic oncology group study. <i>Gynecologic Oncology</i> , 2018, 150, 300-305.	1.4	17
22	A randomized double-blind placebo-controlled phase II trial comparing gemcitabine monotherapy to gemcitabine in combination with adavosertib in women with recurrent, platinum resistant epithelial ovarian cancer: A trial of the Princess Margaret, California, Chicago and Mayo Phase II Consortia.. <i>Journal of Clinical Oncology</i> , 2019, 37, 5518-5518.	1.6	15
23	Neoadjuvant Chemoradiation Therapy Followed by Extradiscal Hysterectomy in Locally Advanced Type II Endometrial Cancer Clinically Extending to Cervix. <i>Practical Radiation Oncology</i> , 2019, 9, 248-256.	2.1	14
24	Risk-Reducing Salpingo-Oophorectomy and Breast Cancer Risk Reduction in the Gynecologic Oncology Group Protocol-0199 (GOG-0199). <i>JNCI Cancer Spectrum</i> , 2020, 4, pkz075.	2.9	11
25	A phase 2 biomarker trial of combination cediranib and olaparib in relapsed platinum (plat) sensitive and plat resistant ovarian cancer (ovca).. <i>Journal of Clinical Oncology</i> , 2018, 36, 5519-5519.	1.6	11
26	Molecular profiles of endometrial cancer tumors among Black patients. <i>Gynecologic Oncology</i> , 2022, 166, 108-116.	1.4	11
27	Contemporary management of uterine clear cell carcinoma: A Society of Gynecologic Oncology (SGO) review and recommendation. <i>Gynecologic Oncology</i> , 2019, 155, 365-373.	1.4	9
28	Outcomes of stage II endometrial cancer: The UPMC Hillman Cancer Center experience. <i>Gynecologic Oncology</i> , 2017, 147, 315-319.	1.4	9
29	Recurrent breast carcinoma presenting as postmenopausal vaginal bleeding: A case report. <i>Gynecologic Oncology Reports</i> , 2014, 10, 38-40.	0.6	8
30	Magnetic resonance imaging response in patients treated with definitive radiation therapy for medically inoperable endometrial cancer—Does it predict treatment response?. <i>Brachytherapy</i> , 2019, 18, 437-444.	0.5	8
31	MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2022, 480, 855-871.	2.8	8
32	Vulvar hemangiopericytoma: A case report and literature review. <i>Gynecologic Oncology Case Reports</i> , 2012, 2, 146-149.	0.9	6
33	A randomized, placebo-controlled phase II trial comparing gemcitabine monotherapy to gemcitabine in combination with AZD 1775 (MK 1775) in women with recurrent, platinum-resistant epithelial ovarian, primary peritoneal, or Fallopian tube cancers: Trial of Princess Margaret, Mayo, Chicago, and California consortia.. <i>Journal of Clinical Oncology</i> , 2015, 33, TPS5613-TPS5613.	1.6	4
34	Overall survival data from a 3-arm, randomized, open-label, phase 2 study of relacorilant, a selective glucocorticoid receptor modulator, combined with nab-paclitaxel in patients with recurrent platinum-resistant ovarian cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, LBA5503-LBA5503.	1.6	4
35	Do air gaps with image-guided vaginal cuff brachytherapy impact failure rates in patients with high-intermediate risk FIGO Stage I endometrial cancer?. <i>Brachytherapy</i> , 2021, 20, 512-518.	0.5	3
36	Updates on uterine papillary serous carcinoma. <i>Expert Review of Obstetrics and Gynecology</i> , 2009, 4, 647-657.	0.4	2

#	ARTICLE	IF	CITATIONS
37	Clinical view of gynecologic intraoperative frozen section diagnosis. <i>Gynecology and Obstetrics Clinical Medicine</i> , 2022, 2, 6-8.	0.5	2
38	LIO-1: Lucitanib + nivolumab in patients with advanced solid tumors—Updated phase 1b results and initial experience in phase 2 ovarian cancer cohort.. <i>Journal of Clinical Oncology</i> , 2021, 39, 5538-5538.	1.6	1
39	Chemo First, Then Radiation, and Perhaps Surgery. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 290-291.	0.8	0
40	HER2 in uterine serous carcinoma: Testing platforms and implications for targeted therapy.. <i>Journal of Clinical Oncology</i> , 2021, 39, 5580-5580.	1.6	0
41	Cost-effectiveness analysis of p53 immunohistochemical testing in stage I and II high-risk endometrial cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, e18838-e18838.	1.6	0
42	Comparing outcomes in robotic-assisted and conventional laparoscopic endometrioid endometrial cancer: A study of practice patterns in 42,197 patients over 2 years.. <i>Journal of Clinical Oncology</i> , 2015, 33, e16524-e16524.	1.6	0
43	Pharmacokinetic and pharmacodynamic analysis of adavosertib in advanced ovarian cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 5579-5579.	1.6	0